BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

• NASDAQ: $BTAI
• Notified: $49.13
• 07:00 EDT